Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers

被引:16
|
作者
Costa, Cristina [1 ]
Migliore, Enrica [2 ,3 ]
Galassi, Claudia [2 ,3 ]
Scozzari, Gitana [4 ]
Ciccone, Giovannino [2 ,3 ]
Coggiola, Maurizio [5 ]
Pira, Enrico [5 ]
Scarmozzino, Antonio [4 ]
La Valle, Giovanni [4 ]
Cassoni, Paola [6 ]
Cavallo, Rossana [1 ]
机构
[1] Univ Hosp Citta Salute & Sci Torino, Microbiol & Virol Unit, I-10126 Turin, Italy
[2] Univ Hosp Citta Salute & Sci Torino, Clin Epidemiol Unit, I-10126 Turin, Italy
[3] CPO Piemonte, I-10126 Turin, Italy
[4] Univ Hosp Citta Salute & Sci Torino, Hosp Med Direct, Osped Molinette, I-10126 Turin, Italy
[5] Univ Hosp Citta Salute & Sci Torino, Occupat Med Unit, I-10126 Turin, Italy
[6] Univ Turin, Dept Med Sci, Pathol Unit, I-10126 Turin, Italy
关键词
SARS-CoV-2; serology; mRNA vaccination; health care workers; IMMUNE-RESPONSE; INFECTION;
D O I
10.3390/vaccines10030474
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We aimed at evaluating quantitative IgG response to BNT162b2 COVID-19 vaccine among health care workers (HCW), and exploring the role of demographic, clinical, and occupational factors as predictors of IgG levels. On May 2021, among 6687 HCW at the largest tertiary care University-Hospital of Northwestern Italy, at a median of 15 weeks (Interquartile range-IQR 13.6-16.0) after second-dose, serological response was present in 99.8%. Seropositivity was >97% in all the subgroups, except those self-reporting immunodeficiency (94.9%). Overall, the median serological IgG value was 990 BAU/mL (IQR 551-1870), with most of subjects with previous SARS-CoV-2 infection or with shorter time lapse (2-8 weeks) between vaccination and serology with values in the highest quintile (>2080). At multivariable analysis, significant predictors of lower values were increasing age, male, current smoking, immunodeficiency, recent occupational contacts, and increasing time lapse from vaccination; conversely, previous infection and recent household contacts were significantly associated with higher IgG levels. Subjects with previous infection kept a very high level (around 2000 BAU/mL) up to 120 days. These results, besides supporting a high serological response up to 4-5 months, suggest predictive factors of faster decay of IgG levels that could be useful in tailoring vaccination strategies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers
    Korodi, Monika
    Horvath, Istvan
    Rakosi, Kinga
    Jenei, Zsuzsanna
    Hudak, Gabriella
    Kakes, Melinda
    Dallos-Fejer, Katalin
    Simai, Eniko
    Pall, Orsolya
    Staver, Natalia
    Briciu, Violeta
    Lupe, Mihaela
    Flonta, Mirela
    Alma, Ariana
    Birlutiu, Victoria
    Lupu, Claudia Daniela
    Ghibu, Andreea Magdalena
    Pianoschi, Dana
    Terza, Livia-Maria
    Fejer, Szilard N.
    VACCINE, 2022, 40 (37) : 5445 - 5451
  • [2] Kinetics of Humoral Immunity against SARS-CoV-2 in Healthcare Workers after the Third Dose of BNT162b2 mRNA Vaccine
    Grassi, Tiziana
    Lobreglio, Giambattista
    Panico, Alessandra
    Rosato, Chiara
    Zizza, Antonella
    Lazzari, Roberta
    Chicone, Michele
    Indino, Floriano
    Bagordo, Francesco
    VACCINES, 2022, 10 (11)
  • [3] IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity
    Bates, John T.
    Farmer, Andrew P.
    Bierdeman, Michael A.
    Ederer, Dallas R.
    Carney, Lauren S.
    Montgomery, Denise D.
    Lirette, Seth T.
    Marshall, Gailen D.
    VACCINES, 2022, 10 (04)
  • [4] Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
    Grupel, Daniel
    Gazit, Sivan
    Schreiber, Licita
    Nadler, Varda
    Wolf, Tamar
    Lazar, Rachel
    Supino-Rosin, Lia
    Perez, Galit
    Peretz, Asaf
    Ben Tov, Amir
    Mizrahi-Reuveni, Miri
    Chodick, Gabriel
    Patalon, Tal
    VACCINE, 2020, 39 (38) : 5337 - 5340
  • [5] Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
    Zaffina, Salvatore
    Alteri, Claudia
    Ruggiero, Alessandra
    Cotugno, Nicola
    Vinci, Maria Rosaria
    Camisa, Vincenzo
    Santoro, Anna Paola
    Brugaletta, Rita
    Deriu, Gloria
    Mortari, Eva Piano
    Salinas, Ane Fernandez
    Russo, Cristina
    Ranno, Stefania
    Coltella, Luana
    Colagrossi, Luna
    Porzio, Ottavia
    Muda, Andrea Onetti
    Raponi, Massimiliano
    degli Atti, Marta Ciofi
    Rizzo, Caterina
    Villani, Alberto
    Rossi, Paolo
    Palma, Paolo
    Carsetti, Rita
    Perno, Carlo Federico
    JOURNAL OF VIRUS ERADICATION, 2021, 7 (02)
  • [6] BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers
    Pratesi, Federico
    Caruso, Teresita
    Testa, Davide
    Tarpanelli, Tiziano
    Gentili, Alessandra
    Gioe, Davide
    Migliorini, Paola
    VACCINES, 2021, 9 (06)
  • [7] Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers
    Tamura, Miku
    Fujita, Retsu
    Sato, Tomoaki
    Sato, Ryohei
    Kato, Yasuyuki
    Nagasawa, Mitsuaki
    Matsumoto, Tetsuya
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (11) : 1478 - 1482
  • [8] Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Psichogiou, Mina
    Karabinis, Andreas
    Poulakou, Garyphallia
    Antoniadou, Anastasia
    Kotanidou, Anastasia
    Degiannis, Dimitrios
    Pavlopoulou, Ioanna D.
    Chaidaroglou, Antigoni
    Roussos, Sotirios
    Mastrogianni, Elpida
    Eliadi, Irene
    Basoulis, Dimitrios
    Petsios, Konstantinos
    Leontis, Konstantinos
    Kakalou, Eleni
    Protopapas, Konstantinos
    Jahaj, Edison
    Pratikaki, Maria
    Syrigos, Konstantinos N.
    Lagiou, Pagona
    Gogas, Helen
    Tsiodras, Sotirios
    Magiorkinis, Gkikas
    Paraskevis, Dimitrios
    Sypsa, Vana
    Hatzakis, Angelos
    VACCINES, 2021, 9 (09)
  • [9] Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort
    Sosic, Lara
    Paolucci, Marta
    Duda, Agathe
    Hasler, Fabio
    Walton, Senta M.
    Kuendig, Thomas M.
    Johansen, Pal
    IMMUNITY INFLAMMATION AND DISEASE, 2022, 10 (03)
  • [10] SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up
    Mastroianni, Franco
    Guida, Pietro
    Bellanova, Grazia
    De Nicolo, Edy Valentina
    Righetti, Giulia
    Formoso, Maurizio
    Celani, Fabrizio
    VACCINE: X, 2022, 11